Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,280 active trials259 approved drugs3,813 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics465
Variants & evidence3813
Drugs427
Trials91351
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,399)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,751–3,775 of 4,399 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
· Science · 2013 · PMID 23558169 · validated civic_curation pubmed
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
· Cell Rep · 2014 · PMID 25199829 · validated civic_curation pubmed
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.
· Cell Rep · 2014 · PMID 24685132 · validated civic_curation pubmed
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.
· Cancer Cell · 2016 · PMID 26725216 · validated civic_curation pubmed
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
· Proc Natl Acad Sci U S A · 2009 · PMID 19122144 · validated civic_curation pubmed
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
· Mol Cancer · 2014 · PMID 24898067 · validated civic_curation pubmed
Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.
· Mol Cancer Ther · 2014 · PMID 24899684 · validated civic_curation pubmed

Showing 3,751–3,775 of 4,399 publications

← Previous
1
…
150
151
152
…
176
Next →

HER2 activating mutations are targets for colorectal cancer treatment.

· Cancer Discov · 2015 · PMID 26243863 · validated civic_curation pubmed

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

· Cancer Res · 2008 · PMID 18593892 · validated civic_curation pubmed

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

· Oncogene · 2011 · PMID 21258415 · validated civic_curation pubmed

Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.

· PLoS One · 2011 · PMID 21494621 · validated civic_curation pubmed

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

· Cancer Discov · 2016 · PMID 26554404 · validated civic_curation pubmed

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

· Cancer Discov · 2014 · PMID 24675041 · validated civic_curation pubmed

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

· Mol Cancer Ther · 2014 · PMID 24608574 · validated civic_curation pubmed

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.

· Proc Natl Acad Sci U S A · 2013 · PMID 23431193 · validated civic_curation pubmed

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.

· Nature · 2016 · PMID 27279227 · validated civic_curation pubmed

MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.

· J Thorac Oncol · 2011 · PMID 21716144 · validated civic_curation pubmed

FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.

· Science · 2008 · PMID 18787170 · validated civic_curation pubmed

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.

· Sci Transl Med · 2016 · PMID 26936505 · validated civic_curation pubmed

Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.

· Nat Med · 2016 · PMID 27500726 · validated civic_curation pubmed

Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.

· Pigment Cell Melanoma Res · 2014 · PMID 24112705 · validated civic_curation pubmed

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

· Nature · 2014 · PMID 24670642 · validated civic_curation pubmed

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

· Cancer Res · 2016 · PMID 27671675 · validated civic_curation pubmed

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

· Clin Cancer Res · 2017 · PMID 27663592 · validated civic_curation pubmed

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

· Cancer Discov · 2015 · PMID 26359368 · validated civic_curation pubmed